Home / Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis
Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis
Feyerabend S. 1,
Saad F. 2,
Ito T. 3,
Diels J. 4,
Van Sanden S. 4,
De Porre P. 5,
Roiz J. 6,
Abogunrin S. 7,
Koufopoulou M. 7,
Fizazi K. 8
1
Studienpraxis Urologie, Dept. of Urologic, Oncology, Nürtingen, Germany 2
Centre Hospitalier de l‘Université de Montréal/CRCHUM, Dept. of Urologic, Oncology, Montréal, Canada 3
Janssen, Dept. of Health Economics & Market Access EMEA, High Wycombe, United Kingdom 4
Janssen, Dept. of Health Economics & Market Access EMEA, Beerse, Belgium 5
Janssen, Dept. of Research & Development, Clinical Oncology, Beerse, Belgium 6
Evidera, Dept. of Modelling and Simulation, London, United Kingdom 7
Evidera, Dept. of Meta Research, London, United Kingdom 8
University of Paris Sud, Gustave Roussy, Villejuif, France
